The benefit was seen as soon as 3 months. Investigators say there should be no delaying treatment for eligible patients.

Digital programs incorporating behavioral therapy led to solid reductions in body weight, and did so at lower drug doses.

Tirzepatide slashed weight by 20%, leading researchers to call this a new “golden age” for weight-loss therapies.

This can be an important add-on to echocardiography in patients with a borderline need for intervention, researchers say.

The multidisciplinary care required to treat these complex patients is most often found in higher-volume centers.

Approximately one in four patients died, deteriorated to a higher shock stage, or were transferred for a higher level of care ...

Individuals assigned male at birth who were pushed to change their identity had more inflammation and higher blood pressure.

By group, procedural success and freedom from LVOT obstruction (LVOT mean gradient > 50 mm Hg), the primary efficacy endpoint ...

With its twice-yearly dosing, the siRNA-based drug might lead to better compliance with treatment. Still, cost is an issue.

Telling patients how many extra days they’ll be free from an event can help with shared decision-making, experts say.

The novel CETP inhibitor, once tested for the now-defunct pathway of HDL raising, reduces LDL as well as Lp(a).

With volume predicted to rise at ASCs the coming decade, it will be important to keep tabs on outcomes and adverse events.